report, there have been considerable changes in the clinical practice of SOT, as well as improvement in TB diagnostics. Guidelines regarding both the prevention approach to TB and treatment of TB disease among SOT recipients are limited and extrapolated mainly from the guidelines in the general population. We therefore aimed this comprehensive review to provide an update on the epidemiology, clinical characteristics, treatment, and outcome of TB after SOT.
| ME THODS
Using MEDLINE, EMBASE, and OVID, we identified all cases of M. tuberculosis after SOT from January 1, 1998, to December 31, 2016. We searched using keywords Mycobacterium tuberculosis or tuberculosis (TB) and transplantation. We used MESH terms and combined tuberculosis with the type of transplant (eg, kidney transplant AND tuberculosis; liver transplant AND tuberculosis). Article references were extensively reviewed for additional cases. Our review was limited to publications in English. All reports of adult SOT recipients who developed TB after transplantation within the study period were eligible for study inclusion and screened by both authors (CLA and RRR). We excluded pediatric cases, cases of TB diagnosed prior to transplant, and hematopoietic stem cell transplantation (HSCT). Reports with mixed non-SOT populations, those with nontuberculous mycobacteria, and where information could not be extracted in detail were excluded.
Duplicate reports from the same institution were excluded. Data were extracted (CLA) and coded in an Excel spreadsheet.
A patient was considered to have TB if the organism was detected by polymerase chain reaction (PCR) or culture in any body fluid or tissue specimen or if acid-fast bacilli or caseating granulomas were documented along with compatible clinical presentation and treatment responses. Fever of unknown origin that was assumed to be due to TB was excluded only if a definitive diagnosis of M. tuberculosis infection was not pursued or documented.
Pulmonary TB (PTB) was defined as TB disease of the respiratory system alone, including the larynx, lung, or pleura. Extrapulmonary TB (EPTB) was defined as TB at a single site outside the respiratory system, while disseminated TB (DTB) was defined as detection of TB in blood, noncontiguous organs, or multiple sites. Donor-derived TB was considered proven if donor and recipient isolates were identical or clonal through molecular analysis, probable if donor and recipient shared both epidemiologic and clinical features, or possible if only epidemiologic criteria were met.
| Statistical analysis
Detailed case reports and cohorts are described separately and/or in combination, as appropriate. Accordingly, the denominator for each variable varies depending on the detail of each report. The incidence of TB, where applicable, was calculated using the following formula: total number of TB cases/total number of transplanted population ×100. The chi-square or Fisher's exact test was used to compare categorical variables; the MannWhitney U test or t test was used to compare continuous variables. were case reports or series, while the remainder were retrospective studies (n = 43), 40, 138, 139, [141] [142] [143] [144] [145] [146] [147] [148] 150, [152] [153] [154] [156] [157] [158] [159] [160] [161] [162] 164, [166] [167] [168] [169] [170] [173] [174] [175] [176] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] case-control studies (n = 5), 140, 163, 171, 172, 177 population-based studies (n = 3), 149, 151, 178 and one prospective study. 165 Most were from Asia (n = 72) and Europe (n = 66), followed by the United States (n = 25), South America (n = 13), Africa (n = 8), and Australia (n = 3).
| RE SULTS

| Epidemiology and demographic characteristics
| Overall population
The majority of the 2082 cases were kidney recipients (n = 1719 and only 1 of 3 case reports specifically mentioned use of CD4-depleting agents. 71 Acute rejection was reported in 4 of 6 patients. 24, 50, 83 Of the 8 KP transplant cases, only 2 case reports had patientlevel data 34, 116 ; the median age was 43.5 years. Only 1 had history of rejection and use of a CD4-depleting agent prior to TB. Both were on a CSA-sparing immunosuppressive regimen.
| Kidney transplant recipients
The incidence of TB among heart recipients based on 7 studies was 1.46%, compared to 0.96% among lung recipients and 1.25%
among kidney-pancreas recipients. cases, of which 2 were given before transplant.
| Mode of TB
| Donor-derived TB
Twenty-three cases of donor-derived TB (DDTB) were identified (Table 2) . 2, 4, 12, 22, 24, 33, 39, 47, 55, 70, 71, 83, 93, 104, 125, 127, 133 Thirteen (56.52%) were proven by molecular analysis. There were 13 males (56.52%). The median age was 50 years (range, 23-68 years).
Most cases were lung recipients (n = 10), followed by kidney (n = 7), liver (n = 5), and heart (n = 1) recipients. The median time to DDTB was 3 months (range 0.2-29 months). Fever was the most common presenting symptom (12/21, 57.14%), although 4
were asymptomatic (4/21, 19.05%). PTB was the most common presentation (n = 9) followed by EPTB (n = 8) and DTB (n = 6). Other extrapulmonary sites are enumerated in Table 4 . (Table 4) . Table 4 .
| Liver transplant recipients
TA B L E 2 Donor-derived TB infections
The majority of patients with DTB had pulmonary involvement (n = 2), genitourinary (n = 2), peritoneum (n = 2), skin (n = 2), bone marrow (n = 1), spine (n = 1), and axilla (n = 1).
| Heart transplant recipients
Of 77 heart recipients, 55 were part of combined cohorts where patient-level data could not be extracted. Of the remaining 22 heart recipients, the most common form was PTB (54.44% [12/22] with PTB who had a normal chest x-ray, 9 patients with PTB and DTB with lung involvement had abnormal radiographic findings (Table 4 ).
| Lung transplant recipients
Among lung recipients, PTB was the most common presentation (78.95% [15/19] ); there were 2 cases of DTB (both with lung involvement) and 2 cases of EPTB (one with cardiac abscess and one with lymph node TB). Median time to presentation was only calculable for DTB and PTB, at 53 and 3 months, respectively. Fever was present in 50% of cases (9/18). Chest radiographic findings were reported in 18 of 20 patients (Table 4) . (1) Normal (6) Cavitary ( 
Myocardial abscess (1), LN (1) CNS, central nervous system; D, disseminated; E, extrapulmonary; GI, gastrointestinal; GU, genitourinary; LL, lower lobe; LN, lymph node; MSK/SST, musculoskeletal/skin soft tissue; P, pulmonary; Pl Eff, pleural effusion; UL, upper lobe.
a One patient may have more than one radiographic finding. 
| Treatment of TB in SOT recipients
| Clinical outcome of TB in SOT recipients
Overall, the mortality rate of SOT recipients was 18.84% (269/1428).
The mortality rates among kidney, liver, heart, and lung recipients 
| D ISCUSS I ON
This large comprehensive contemporary review of TB in SOT recipients demonstrates (i) variable incidence depending on the location;
(ii) reactivation TB as the more common mechanism, although there is also a fair number of DDTB; (iii) variable clinical and radiologic manifestations, with high rates of EPTB and DTB; (iv) complex multidrug treatment, associated with anticipated drug toxicity and allograft dysfunction; and (v) high rates of all-cause mortality.
While the overall incidence of TB among SOT recipients was relatively low at 2.37%, this is still several-fold higher compared to the general population. 190 Our review also highlights the geographic predilection of TB, which is highly prevalent in endemic countries located mostly in Asia and Africa. Extensive knowledge of both the donor and recipient's history is imperative, as they would drive the initiative to pursue a more extensive TB-specific evaluation.
The majority of cases consisted mostly of kidney transplant recipients, and this is likely due to the overall large number of kidney transplant recipients compared to all other transplants, especially in TB-endemic regions (where the more complex heart, lung, and pancreas transplant procedures are performed less commonly).
Overall, onset of TB in the majority of cases occurred beyond the first year after transplantation. This is consistent with the presumed mechanism of reactivation of latent TB. It is notable, however, that 40% of cases reactivated within 12 months, a reminder to transplant physicians that the possibility of TB should not be discounted in the early post-transplant period. In fact, for non-kidney transplant recipients, the onset of disease occurred much earlier, which may reflect the greater degree of immune suppression when compared to kidney recipients.
Earlier onset of disease is also observed in our DDTB cases, 199 Most SOT recipients with TB recovered clinically without long-term sequelae. Overall, all-cause mortality in our cohort was 18.84%, and this was lower than the 29% cited in the prior review 2 decades ago. Notably, mortality rates were higher among non-kidney transplants, possibly again reflective of the net state of immune suppression in these SOT recipients. The TB-attributable mortality rate was 9.75% (137/1405). The reported decrease in mortality may be due to our larger study population (1428 vs 499), but it could also be due to advancements in TB diagnosis over the last 2 decades, including the advent of rapid tests such as the interferon gamma release assay and polymerase chain reaction for screening of latent TB infection and diagnosis of active infection, respectively, which may have expedited early diagnosis and treatment.
Our study has limitations inherent to its retrospective nature.
First, there was some variation of TB classification across studies, although we attempted to standardize definitions. Second, the study spanned 2 decades, and changes in standard practice, such as isoniazid prophylaxis, could have affected TB incidence. We also limited our review to the English language, and important publications may have been missed. Third, given the heterogeneity of cases, we were unable to do a formal meta-analysis or systematic review. We aimed only to provide a summary of all detailed TB cases reported since the last review in 1998. Despite these limitations, our study is the only comprehensive study on TB among SOT recipients in the last 20 years and includes 2,082 cases.
| CON CLUS IONS
Our review confirms that TB in SOT recipients is associated with difficult clinical challenges related to its diagnosis and treatment. TB remains associated with significant morbidity and mortality after SOT. TB typically occurs after the first year of transplantation for kidney recipients, while an earlier onset is observed in other SOT recipients. DDTB infection should also be highly considered when TB occurs within the first 3 months, as this would trigger the evaluation of other recipients with the same donor. EPTB and DTB are not uncommon clinical presentations. Often, persistent fever is the only symptom of active TB disease. Treatment of active TB disease is often complicated by unavoidable drug-drug interactions, risk of hepatotoxicity, and risk of allograft rejection.
CO N FLI C T O F I NTE R E S T
Both authors have no conflict of interests to declare.
AUTH O R S' CO NTR I B UTI O N S
CLA: Collected data; both authors: Contributed to data analysis, research design, and discussion.
O RCI D
Cybele Lara R. Abad http://orcid.org/0000-0002-5183-8239
